Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 69, Issue 9, 2014, Pages 1122-1131

  Rizzo, Maria Rosaria ^a   Barbieri, Michelangela ^a   Boccardi, Virginia ^a   Angellotti, Edith ^a   Marfella, Raffaele ^a   Paolisso, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

DPP 4 inhibitor treatment; Mild cognitive impairment; Older patients with type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; BODY MASS; COGNITION; DPP-4 INHIBITOR TREATMENT; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MILD COGNITIVE IMPAIRMENT.; NON INSULIN DEPENDENT DIABETES MELLITUS; OLDER PATIENTS WITH TYPE 2 DIABETES; RETROSPECTIVE STUDY;

DPP-4 INHIBITOR TREATMENT; MILD COGNITIVE IMPAIRMENT.; OLDER PATIENTS WITH TYPE 2 DIABETES;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; COGNITION; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METFORMIN; MILD COGNITIVE IMPAIRMENT; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 84906246754     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glu032     Document Type: Article

References (48)

1. Messier C, Gagnon M. Cognitive decline associated with dementia and type 2 diabetes: The interplay of risk factors. Diabetologia; 2009;52:2471-2474. doi:10.1007/s00125-009-1533
2. Roberts RO, Geda YE, Knopman DS, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol. 2008;65:1066-1073. doi:10.1001/archneur.65.8.1066
3. Sue Kirkman M, Briscoe VJ, Clark N, et al.; Consensus Development Conference on Diabetes and Older Adults. Diabetes in older adults: A consensus report. J Am Geriatr Soc. 2012;60(12):2342-2356. doi:10.1111/jgs.12035
4. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol. 2012;69(9):1170-1175. doi:10.1001/archneurol.2012.1117
5. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in Diabetes mellitus: A systematic review. Lancet Neurol. 2006;5:64-74
6. Reijmer YD, van Den Berg E, Ruis C, Kappelle LJ, Biessels GJ. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev. 2010;26:507-519. doi:10.1002/dmrr.1112. Review
7. Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: Position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13(6):497-502. doi:10.1016/j.jamda.2012.04.012
8. Wessels AM, Scheltens P, Barkhof F, Heine RJ. Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol. 2008;585(1):88-96. doi:10.1016/j.ejphar.2007.11.080
9. Maggi S, Limongi F, Noale M, et al.; ILSA Study Group. Diabetes as a risk factor for cognitive decline in older patients. Dement Geriatr Cogn Disord. 2009;27(1):24-33. doi:10.1159/000183842
10. Shorr RI, de Rekeneire N, Resnick HE, et al. Glycemia and cognitive function in older adults using glucose-lowering drugs. J Nutr Health Aging. 2006;10:297-301
11. Folli F, Guzzi V, Perego L, et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS One. 2010;5(3):e9923. doi:10.1371/journal.pone.0009923
12. Ceriello A, Novials A, Ortega E, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013;36:2346-2350. doi:10.2337/dc12-2469
13. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in Diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19:5695-5703
14. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687
15. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13(8):813-818. doi:10.1089/dia.2011.0049
16. Bauduceau B, Doucet J, Bordier L, Garcia C, Dupuy O, Mayaudon H. Hypoglycaemia and dementia in Diabetic patients. Diabetes Metab. 2010;36(suppl 3):S106-S111. doi:10.1016/S1262-3636(10)70476-6
17. Rizzo MR, Marfella R, Barbieri M, et al. Relationships between Daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care. 2010;33(10):2169-2174. doi:10.2337/dc10-0389
18. L auner LJ, Miller ME, Williamson JD, et al.; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy. Lancet Neurol. 2011;10:969-977. doi:10.1016/S1474-4422(11)70188-0
19. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc. 1993;41:1305-1312
20. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry. 2005;13:950-958
21. Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706-1711. doi:10.2337/dc09-2030
22. Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1 (diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res. 2008;33(9):1845-1851. doi:10.1007/s11064-008-9646-4
23. L iu JH, Yin F, Guo LX, Deng XH, Hu YH. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: Involvement of PI3 kinase signal pathway. Acta Pharmacol Sin. 2009;30(2):159-165. doi:10.1038/aps.2008.25
24. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res. 2005;2(3):377-385
25. L i L. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?. Neurosci Bull. 2007;23(1):58-65
26. Holscher C. Incretin analogues that have been Developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov. 2010;5(2):109-117
27. Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: A matching-Adjusted indirect comparison of randomized trials. Clin Drug Investig. 2011;31(9):665-674. doi:10.2165/11592490-000000000- 00000
28. Guerci B, Monnier L, Serusclat P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study. Diabetes Metab. 2012;38(4):359-366. doi:10.1016/j.diabet.2012.06.001
29. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012;11:92. doi:10.1186/1475-2840-11-92
30. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications. 2010;24(2):79-83. doi:10.1016/j.jdiacomp.2009.01.004
31. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in Different Ethnic Groups. Diabetes Technol Ther. 2011;13:921-928. doi:10.1089/dia.2010.0247
32. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644-655
33. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253-263
34. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in Diabetes: A report from the American Diabetes Association - Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249
35. Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia?. Diabetes Care. 2002;25(5):889-893
36. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin. 2007;25(3):577-609
37. Mitchell AJ. A meta-Analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43(4):411-431. doi:10.1016/j. jpsychires.2008.04.014
38. Cullen B, Fahy S, Cunningham CJ, et al. Screening for dementia in an Irish community sample using MMSE: A comparison of norm-Adjusted versus fixed cut-points. Int J Geriatr Psychiatry. 2005;20:371-376
39. Christa Maree Stephan B, Minett T, Pagett E, Siervo M, Brayne C, McKeith IG. Mild cognitive impairment (MCI) in clinical trials: A systematic review. BMJ Open. 2013;3:e001909. doi:10.1136/bmjopen-2012-001909
40. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol. 1996;36:378-384
41. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29:345-351
42. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-Analysis of longitudinal studies. Intern Med J. 2012;42(5):484-491. doi:10.1111/j.1445-5994.2012.02758.x
43. Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al.; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: The action to control cardiovascular risk in Diabetes-memory in Diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32(2):221-226. doi:10.2337/dc08-1153
44. Zhong Y, Zhang XY, Miao Y, et al. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomed Environ Sci. 2012;25(1):1-7. doi:10.3967/0895-3988.2012.01.001
45. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076-2082
46. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci. 2011;1243:E55-E74. doi:10.1111/j.1749-6632.2012.06491.x. Review
47. Mossello E, Ballini E, Boncinelli M, et al. Glucagon-like peptide-1, diabetes, and cognitive decline: Possible pathophysiological links and therapeutic opportunities. Exp Diabetes Res. 2011;2011:281674. doi:10.1155/2011/281674
48. Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: More benefits or risks?. Adv Ther. 2012;29(3):218-233. doi:10.1007/s12325-012-0008-x